Discuss your experiences with the benefits, risks, and side effects of immunotherapy treatment for breast cancer.
Posted on: Mar 8, 2019 03:54PM
Tecentriq Approved as First Immunotherapy for Breast Cancer
March 8, 2019
On March 8, 2019, the FDA approved Tecentriq in combination with the chemotherapy medicine Abraxane as a first treatment for unresectable locally advanced or metastatic triple-negative, PD-L1-positive breast cancer. Read more...